The clinician applies clinical decision-making logic to choose between rate control and rhythm control strategies in atrial fibrillation management. The AFFIRM trial demonstrated no mortality difference between strategies, but subsequent analysis and the EAST-AFNET 4 trial showed that early rhythm control (within 1 year of diagnosis) reduced cardiovascular events. Rate control is preferred when: patient is asymptomatic or minimally symptomatic with adequate rate control, the patient is elderly with multiple comorbidities, left atrial diameter is significantly enlarged (greater than 55 mm -- low probability of maintaining sinus rhythm), AF duration is greater than 12 months, or the patient prefers to avoid antiarrhythmic drugs. Rhythm control is preferred when: patient remains symptomatic despite adequate rate control, young or active patient desiring normal sinus rhythm, first episode of AF, tachycardia-mediated cardiomyopathy, or early AF (less than 1 year). Pharmacological rhythm control selection depends on cardiac structure: no structural heart disease -- flecainide or propafenone (Class IC, contraindicated in coronary artery disease, HFrEF, or significant LVH due to proarrhythmic risk); heart failure -- amiodarone (most effective but significant toxicity profile requiring monitoring: thyroid...